Children's National Medical Center, Division of Neurogenetics and Neurodevelopmental Pediatrics, Washington, DC 20010, USA.
Department of Anatomy and Cell Biology, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.
Neurotherapeutics. 2024 Jan;21(1):e00311. doi: 10.1016/j.neurot.2023.e00311. Epub 2024 Jan 19.
Mitochondrial disorders are a group of rare and heterogeneous genetic diseases characterized by dysfunctional mitochondria leading to deficient adenosine triphosphate synthesis and chronic energy deficit in patients. The majority of these patients exhibit a wide range of phenotypic manifestations targeting several organ systems, making their clinical diagnosis and management challenging. Bridging translational to clinical research is crucial for improving the early diagnosis and prognosis of these intractable mitochondrial disorders and for discovering novel therapeutic drug candidates and modalities. This review provides the current state of clinical testing in mitochondrial disorders, discusses the challenges and opportunities for converting basic discoveries into clinical settings, explores the most suited patient-centric approaches to harness the extraordinary heterogeneity among patients affected by the same primary mitochondrial disorder, and describes the current outlook of clinical trials.
线粒体疾病是一组罕见且异质性的遗传疾病,其特征为功能失调的线粒体导致患者体内三磷酸腺苷合成不足和慢性能量亏缺。这些患者大多表现出针对多个器官系统的广泛表型表现,这使得其临床诊断和管理具有挑战性。将转化研究应用于临床研究对于改善这些难治性线粒体疾病的早期诊断和预后,以及发现新的治疗药物候选物和方法至关重要。本文综述了线粒体疾病的临床检测现状,讨论了将基础发现转化为临床应用的挑战和机遇,探讨了最适合以患者为中心的方法来利用同一原发性线粒体疾病患者之间的巨大异质性,并描述了临床试验的现状。